

Mail Stop 6010

November 8, 2007

Lynne Hohlfeld  
Chief Financial Officer  
Opexa Therapeutics, Inc.  
2635 North Crescent Ridge Drive  
The Woodlands, Texas 77381

**Re: Opexa Therapeutics, Inc.  
Registration Statement on Form SB-2  
Filed November 6, 2007  
File No. 333-147167**

Dear Ms. Hohlfeld:

We have limited our review of your filing to those issues we have addressed in our comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. After reviewing this information, we may raise additional comments.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

General

1. We note you have an open confidential treatment application. The processing of this application will need to be complete, and all comments will need to be resolved, prior to the effectiveness of the registration statement.
2. All comments related to the ongoing accounting review of your 2006 Form 10-K will need to be resolved prior to the effectiveness of this registration statement.

Prospectus Cover Page

3. We note you are registering the same number of shares and warrants. Please disclose whether you are offering these securities separately or together as units. If they will be sold as units, disclose whether the shares and warrants will be able to trade separately.
4. Please provide pricing information regarding the warrants and, if units will be offered, the units. The disclosure should comply with Item 501(b)(3) of Regulation S-K and the corresponding instructions.

\* \* \*

As appropriate, please amend your registration statement in response to these comments. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information required under the Securities Act of 1933 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

Notwithstanding our comments, in the event the company requests acceleration of the effective date of the pending registration statement, it should furnish a letter, at the time of such request, acknowledging that:

- should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
- the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
- the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Lynne Hohlfeld  
Opexa Therapeutics, Inc.  
November 8, 2007  
Page 3

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in connection with our review of your filing or in response to our comments on your filing.

We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the securities specified in the above registration statement. We will act on the request and, pursuant to delegated authority, grant acceleration of the effective date.

We direct your attention to Rules 460 and 461 regarding requesting acceleration of a registration statement. Please allow adequate time after the filing of any amendment for further review before submitting a request for acceleration. Please provide this request at least two business days in advance of the requested effective date.

Please contact Greg Belliston at (202) 551-3861 or me at (202) 551-3715 with any questions.

Sincerely,

Jeffrey P. Riedler  
Assistant Director

cc: Michael C. Blaney, Esquire  
Vinson & Elkins L.L.P.  
1001 Fannin, Suite 2300  
Houston, TX 77002